Skip to Content
Merck
  • Antihistamine pretreatment to reduce incidence of withdrawal movement after rocuronium injection.

Antihistamine pretreatment to reduce incidence of withdrawal movement after rocuronium injection.

Journal of Korean medical science (2009-10-02)
Ho Jun Lee, Sung Jin Han, Heezoo Kim, Il Ok Lee, Myoung Hoon Kong, Nan Suk Kim, Sang Ho Lim, Mi Kyoung Lee
ABSTRACT

The purpose of this study was to determine the effectiveness of antihistamine therapy for withdrawal movements caused by rocuronium injection. One hundred seventy one ASA I-II adults undergoing elective surgery were randomly assigned to one of two groups. Patients in the control group (Group C) were premedicated with 2 mL normal saline, and those in the antihistamine group (Group A) were pre-medicated with 2 mL (45.5 mg) pheniramine maleate. After the administration of thiopental sodium 5 mg/kg, rocuronium 0.6 mg/kg was injected. Withdrawal movements were assessed using a four-grade scale. The administration of antihistamine reveals lower grade of withdrawal movement after rocuronium injection.

MATERIALS
Product Number
Brand
Product Description

Supelco
Pheniramine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Pheniramine maleate salt